GH Research (GHRS) Reports Q3 Net Loss of $1.8M, Cash Position of $280.7M, Issues Business Updates

Go back to GH Research (GHRS) Reports Q3 Net Loss of $1.8M, Cash Position of $280.7M, Issues Business Updates

GH Research (GHRS) Reports Successful Outcome of the Phase 2 part of its Phase 1/2 Clinical Trial of GH001

December 6, 2021 7:00 AM EST

GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported the successful outcome of the Phase 2 part of a Phase 1/2 clinical trial of GH001, an inhalable 5-MeO-DMT product candidate, in patients with treatment-resistant... More